See also this year's filing and all EDGAR filings for this company.
PDF Report 0001534248_2020_Chemomab_Therapeutics_Ltd.pdf
Logs
| warning | Missing logo | subcommand.report | {} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 0.02995335133808004, 'aggregate_val': 19755000, 'exp_sum': 20365000, 'exp_to_value': {'AssetsCurrent': 18211000, 'IntangibleAssetsNetIncludingGoodwill': 0, 'PropertyPlantAndEquipmentNet': 158000, 'remainder_Assets': 1996000}} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0001534248')"} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001534248, Chemomab Therapeutics Ltd.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 18,211,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 158,000 |
| 3 | remainder_Assets | 1,386,000 |
| 4 | LiabilitiesCurrent | 4,121,000 |
| 5 | LiabilitiesNoncurrent | 725,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 6,245,000 |
| 9 | ResearchAndDevelopmentExpense | 13,303,000 |
| 10 | remainder_Expenses | 3,350,000 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 4,226,000 |
| 13 | remainder_ComprehensiveNetIncome | 54,248,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 19,755,000 |
| 1 | Liabilities | 4,846,000 |
| 2 | Expenses | 22,898,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 14,909,000 |
| 5 | NetIncome | -18,672,000 |
| 6 | ComprehensiveNetIncome | 8,452,000 |
| 7 | BaseVar | 52,986,500 |
| 8 | EconomicCapitalRatio | 2.77 |
Edgar->Model Mapping
Feature Distribution
Change over Time
